Ongoing Registry of Deep Venous Reconstructions
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Jan 7, 2016
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Ongoing Registry of Deep Venous Reconstructions, is looking at how effective certain treatments are for patients with blockage in their deep veins, specifically in areas like the femoral vein and iliac veins. The treatments being studied include a procedure known as percutaneous transluminal angioplasty (PTA), where a small balloon is used to open up the blocked vein, as well as the placement of a stent to keep the vein open. Some patients may also undergo a surgical procedure to remove blockages.
To be eligible for this trial, participants must have a blockage in one of the targeted veins, but they cannot have a life expectancy of less than one year or be unable to tolerate blood-thinning medications. This study is currently recruiting participants of all ages and genders. Those who join the trial can expect to receive one of these treatments and will be monitored throughout the process to see how well it helps improve their condition. It's an important opportunity to contribute to the understanding and improvement of treatments for venous thrombosis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Venous obstruction/occlusion in the femoral vein, common femoral vein, external iliac vein, common iliac vein or inferior vena cava
- Exclusion Criteria:
- • Intolerance to anticoagulant medication
- • A life expectancy \<1 year
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, , Netherlands
Maastricht, , Netherlands
Patients applied
Trial Officials
Cees Wittens, MD, PhD
Principal Investigator
Maastricht University Medical Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials